Iovance Biotherapeutics, Inc. IOVA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 36.7%+5.4pp | 31.3%+1.5pp | 29.9%-0.3pp | 30.2%-2.4pp | 32.6%-1.6pp | |
| Operating margin | -127.2%+25.9pp | -153.1%+13.2pp | -166.3%+3.7pp | -170%+17.5pp | -187.5%+53.4pp | |
| Net margin | -123.9%+24.5pp | -148.4%+10.4pp | -158.8%+2.7pp | -161.4%+15.1pp | -176.5%+50.3pp | |
| Returns | ||||||
| Return on equity | -47.5%+8.0pp | -55.5%-1.6pp | -53.9%-0.7pp | -53.2%-1.3pp | -51.8%+5.6pp | |
| Return on invested capital | -59.5%+5.7pp | -65.2%0.0pp | -65.2%+1.4pp | -66.6%-4.2pp | -62.4%+7.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.6×+0.4× | 3.2×-0.2× | 3.4×+0.1× | 3.3×-0.9× | 4.2×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Valuation | ||||||
| Market capitalization | $1.45B+33.4% | $1.08B+38.0% | $785.22M+25.1% | $627.8M-42.5% | $1.09B-51.6% | |
| Price / sales | 5.1×+1.0× | 4.1×+1.0× | 3.1×+0.5× | 2.6×-2.5× | 5.1×-8.6× | |
| Price / book | 2×+0.5× | 1.6×+0.4× | 1.1×+0.2× | 0.9×-0.5× | 1.4×-1.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Iovance Biotherapeutics, Inc. (IOVA) runs a 36.7% gross margin and a -127.2% operating margin, with a -123.9% net margin.
- Where do Iovance Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Iovance Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
